Articles by Cailin Conner
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
The investigators conceded the longer follow-up is needed but the results are promising.
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Noteworthy regional disparities were noticed in treatment strategies.
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.